Pharmacology/Pharmaceutical Industry
Presented at ASRS Meeting | Studies link GLP-1 agonists to progression of diabetic retinopathy
11 Aug, 2023 | 15:38h | UTCStudies link GLP-1 agonists to progression of diabetic retinopathy – MDedge
M-A | Pharmacist-led home BP telemonitoring enhances control over usual care
11 Aug, 2023 | 15:29h | UTC
Review | Adverse effects of antidepressant medications and their management in children and adolescents
9 Aug, 2023 | 15:25h | UTC
M-A | Absence of evidence for antipsychotics in youth unipolar depression; limited evidence in bipolar depression
9 Aug, 2023 | 15:23h | UTC
M-A | Nearly 37% of elderly outpatients are at risk due to potentially inappropriate medication use
8 Aug, 2023 | 13:37h | UTC
Perspective | Will unpredictable side effects dim the promise of new Alzheimer’s drugs?
8 Aug, 2023 | 13:30h | UTCWill unpredictable side effects dim the promise of new Alzheimer’s drugs? – Science (a few articles per month are free)
Related:
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns
Cohort Study | Habitual calcium supplementation linked to higher CVD incidence and mortality in diabetics
8 Aug, 2023 | 13:24h | UTCAssociations of Habitual Calcium Supplementation With Risk of Cardiovascular Disease and Mortality in Individuals With and Without Diabetes – Diabetes Care (link to abstract – $ for full-text)
Commentary on Twitter
Habitual Ca supplementation was associated with higher risks of CVD in diabetics but not non-diabetics, suggesting that diabetics may need to be cautious about the long-term use of Ca supplements. @ADA_Pubs
Read Here➡️https://t.co/wUBy6KJhaw pic.twitter.com/6FXmwBwnMS
— Diabetes Care, a research journal of the ADA ? (@DiabetesCareADA) July 28, 2023
Opinion Video | Critical analysis of the data behind Covid-19 booster shots
31 Jul, 2023 | 14:40h | UTCOriginal Publication: Correspondence | Potential “healthy vaccinee bias” in a study of BNT162b2 vaccine against Covid-19
New WHO lists of essential medicines
28 Jul, 2023 | 14:23h | UTCNews Release: WHO endorses landmark public health decisions on Essential Medicines for Multiple Sclerosis – World Health Organization
Lists of Essential Medicines
Model Lists of Essential Medicines – World Health Organization
Model Lists of Essential Medicines for Children – World Health Organization
Commentary on Twitter
OUT TODAY: New editions of the WHO Model Lists of Essential Medicines and Essential Medicines for Children which include important new medicines for the treatment of multiple sclerosis, cancer, infectious diseases and cardiovascular conditions, among others… pic.twitter.com/RZYdgc0i65
— World Health Organization (WHO) (@WHO) July 26, 2023
Study | Only 11% of sports supplements listing botanical ingredients accurately declare contents, 12% contain FDA-prohibited stimulants
28 Jul, 2023 | 14:21h | UTCCommentaries:
Ensuring the Safety and Value of Supplements – JAMA Network Open
BMJ Investigation | Medical royal colleges receive millions from drug and medical devices companies
28 Jul, 2023 | 14:19h | UTCMedical royal colleges receive millions from drug and medical devices companies – The BMJ
News Release: Medical royal colleges receive millions from drug/medical device companies – BMJ Newsroom
Commentary on Twitter
Drug and medical device companies have given £9m to UK royal colleges in recent years.
Scroll through our series of #BMJInfographics to see how much individual companies have paid each college ? https://t.co/s03xSl18BP pic.twitter.com/PX1Lzmtb4N
— The BMJ (@bmj_latest) July 27, 2023
Position Paper | Prioritizing deprescribing in fall prevention strategies
28 Jul, 2023 | 14:12h | UTCOriginal Guideline: World guidelines for falls prevention and management for older adults: a global initiative – Age and Ageing
RCT | Vitamin D supplementation shows no cognitive benefit in mild cognitive impairment intervention
25 Jul, 2023 | 14:00h | UTCCommentary: Exercise and Cognitive Training Slow Thinking Declines. Vitamin D? Not So Much – HealthDay
Related:
RCT | No statistically significant impact of vitamin D on major cardiovascular events
2ry analysis of a RCT | Vitamin D supplementation does not affect cognitive function in older adults
Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention
Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases
Systematic Review | Moderate evidence supports interactive mobile phone interventions for contraception use enhancement
25 Jul, 2023 | 13:25h | UTCMobile phone‐based interventions for improving contraception use – Cochrane Library
Review | Research on prescribing cascades
24 Jul, 2023 | 12:53h | UTCResearch on prescribing cascades: a scoping review – Frontiers in Pharmacology
Correspondence | Potential “healthy vaccinee bias” in a study of BNT162b2 vaccine against Covid-19
21 Jul, 2023 | 13:43h | UTC
Commentary from the author on Twitter (thread – click for more)
Our correspondence is out in @njem written w @VPrasadMDMPH & Ram Duriseti
We show v strong evidence of healthy vaccinee bias in an Israeli study of Pfizer booster vs covid death, which wasn't disclosed
Could explain ALL reported benefit of the booster?https://t.co/F3WeafvUnw pic.twitter.com/b29YQ0lblh
— Tracy Høeg, MD, PhD (@TracyBethHoeg) July 20, 2023
Phase 1 Trial | Zilebesiran demonstrates potential as prolonged-action hypertension therapeutic
21 Jul, 2023 | 13:32h | UTCZilebesiran, an RNA Interference Therapeutic Agent for Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Experimental Shot Given Every Six Months Controlled High Blood Pressure in Early Trial – HealthDay
IDSA 2023 Guidance on the treatment of antimicrobial resistant gram-negative infections
20 Jul, 2023 | 11:15h | UTC
Systematic Review | Outcomes in deprescribing implementation trials and compliance with expert recommendations
20 Jul, 2023 | 10:55h | UTCRelated:
RCT | Opioids not more effective than placebo for acute low back and neck pain
RCT | A deprescribing intervention reduced medication burden among older adults in post-acute care
Deprescribing proton pump inhibitors – Australian Journal of General Practice
Antihypertensive Deprescribing in Older Adults: a Practical Guide – Current Hypertension Reports
Deprescribing in Palliative Cancer Care – Life
Less is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review – Kidney360
Polypharmacy Management in Older Patients – Mayo Clinic Proceedings
Eliminating Medication Overload: A National Action Plan – Lown Institute
Common ED Medication Errors: Polypharmacy – emDocs
Current and future perspectives on the management of polypharmacy – BMC Family Practice
Polypharmacy—an Upward Trend with Unpredictable Effects – Deutsches Ärzteblatt international
Clinical Consequences of Polypharmacy in Elderly – Expert Opinion on Drug Safety
FDA approves first nonprescription daily oral contraceptive
19 Jul, 2023 | 14:25h | UTCFDA Approves First Nonprescription Daily Oral Contraceptive – U.S. Food & Drug Administration
RCT | Direct oral challenge noninferior to skin testing followed by direct oral challenge in low-risk penicillin allergy patients
18 Jul, 2023 | 13:54h | UTCEfficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial – JAMA Internal Medicine (free for a limited period)
See also: Visual Abstract
News Release: World-first clinical trial to help millions with penicillin allergies – Vanderbilt University Medical Center
Commentary: Trial supports use of direct oral challenge for penicillin allergy – CIDRAP
RCT | Donanemab slows early symptomatic Alzheimer’s progression, but raises serious safety concerns
18 Jul, 2023 | 13:51h | UTCDonanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial – JAMA (free for a limited period)
Editorials:
Donanemab for Alzheimer Disease—Who Benefits and Who Is Harmed? – JAMA (free for a limited period)
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease – JAMA (free for a limited period)
Ushering in a New Era of Alzheimer Disease Therapy – JAMA (free for a limited period)
See also: Visual Abstract
Commentary: Expert reaction to results from Eli Lilly on its anti-amyloid drug donanemab – Science Media Centre
Related: RCT | Lecanemab slows cognitive decline in early Alzheimer’s disease but raises safety concerns.
Guideline | Antibiotic therapy in patients with suspected antibiotic allergy
17 Jul, 2023 | 13:59h | UTC
Retrospective Analysis | Inconsistencies in pediatric drug dosing found in over half of prehospital emergency drug administrations
17 Jul, 2023 | 13:50h | UTCCommentaries:
Children and Drug Dosing Variations When in Transit to the Hospital – AAP Journals Blog
Variation Seen in Dosing of Meds at Prehospital Pediatric Encounters – HealthDay
Cohort Study | Long-acting antiretroviral therapy may achieve virologic suppression in HIV patients with adherence challenges
17 Jul, 2023 | 13:26h | UTCDemonstration Project of Long-Acting Antiretroviral Therapy in a Diverse Population of People With HIV – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Long-Acting ART Achieves Virologic Suppression for People With HIV – HealthDay